Mark J. Gergen Sells 30,000 Shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX) Stock

Poseida Therapeutics, Inc. (NASDAQ:PSTX) Chairman Mark J. Gergen sold 30,000 shares of the business’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $9.27, for a total transaction of $278,100.00. Following the sale, the chairman now owns 651,291 shares in the company, valued at $6,037,467.57. This trade represents a 4.40 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Poseida Therapeutics Price Performance

NASDAQ:PSTX traded down $0.05 during trading hours on Wednesday, reaching $9.33. 3,346,633 shares of the company’s stock were exchanged, compared to its average volume of 699,993. The company has a quick ratio of 3.20, a current ratio of 3.20 and a debt-to-equity ratio of 0.68. The company has a market capitalization of $909.35 million, a P/E ratio of -14.81 and a beta of 0.54. Poseida Therapeutics, Inc. has a 12 month low of $1.87 and a 12 month high of $9.42. The business’s 50-day simple moving average is $3.02 and its two-hundred day simple moving average is $3.01.

Institutional Investors Weigh In On Poseida Therapeutics

Several large investors have recently modified their holdings of the stock. Marshall Wace LLP purchased a new stake in Poseida Therapeutics during the second quarter valued at about $31,000. Bayesian Capital Management LP purchased a new stake in shares of Poseida Therapeutics in the 1st quarter valued at approximately $33,000. Rothschild Investment LLC purchased a new stake in shares of Poseida Therapeutics in the 2nd quarter valued at approximately $35,000. Principal Financial Group Inc. acquired a new position in Poseida Therapeutics in the 2nd quarter worth approximately $35,000. Finally, Virtu Financial LLC purchased a new position in Poseida Therapeutics during the 3rd quarter worth approximately $37,000. 46.87% of the stock is owned by institutional investors.

Analysts Set New Price Targets

PSTX has been the topic of a number of research analyst reports. William Blair reiterated a “market perform” rating on shares of Poseida Therapeutics in a research note on Tuesday. HC Wainwright reiterated a “neutral” rating and set a $9.00 price target (down from $20.00) on shares of Poseida Therapeutics in a research report on Tuesday. Cantor Fitzgerald lowered Poseida Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday. Finally, BTIG Research reaffirmed a “neutral” rating on shares of Poseida Therapeutics in a report on Tuesday. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $9.50.

Poseida Therapeutics Company Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.